Show simple item record

dc.contributor.authorMontuori, Nunzia
dc.contributor.authorPesapane, Ada
dc.contributor.authorRossi, Francesca Wanda
dc.contributor.authorGiudice, Valentina
dc.contributor.authorDe Paulis, Amato
dc.contributor.authorSelleri, Carmine
dc.contributor.authorRagno, Pia
dc.date.accessioned2020-05-22T12:56:54Z
dc.date.available2020-05-22T12:56:54Z
dc.date.issued2016
dc.identifier.citationMontuori N, Pesapane A, Rossi FW, Giudice V, De Paulis A, Selleri C, Ragno P. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Translational Medicine @ UniSa 2016, 15(3): 15-21.it_IT
dc.identifier.issn2239-9747it_IT
dc.identifier.urihttp://www.translationalmedicine.unisa.it/indexit_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/4481
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2679
dc.description.abstractThe urokinase (uPA)-type plasminogen activator receptor (uPAR) is a GPIanchored receptor that focuses urokinase (uPA) proteolytic activity on the cell surface. uPAR also regulates cell adhesion, migration and proliferation, protects from apoptosis and contributes to epithelial mesenchymal transition (EMT), independently of uPA enzymatic activity. Indeed, uPAR interacts with beta1, beta2 and beta3 integrins, thus regulating their activities. uPAR cross-talks with receptor tyrosine kinases through integrins and regulates cancer cell dormancy, proliferation and angiogenesis. Moreover, uPAR mediates uPA-dependent cell migration and chemotaxis induced by fMet-Leu-Phe (fMLF), through its association with fMLF-receptors (fMLFRs). Further, uPAR is an adhesion receptor because it binds vitronectin (VN), a component of provisional extracellular matrix. High uPAR expression predicts for more aggressive disease in several cancer types for its ability to increase invasion and metastasis. In fact, uPAR has been hypothesized to be the link between tumor cell dormancy and proliferation that usually precedes the onset of metastasis. Thus, inhibiting uPAR could be a feasible approach to affect tumor growth and metastasis. Here, we review the more recent advances in the development of uPAR-targeted anti-cancer therapeutic agents suitable for further optimization or ready for the evaluation in early clinical trials.it_IT
dc.format.extentP. 15-21it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectuPARit_IT
dc.subjectMetastasisit_IT
dc.subjectPlasminogen activationit_IT
dc.subjectMonoclonal antibodyit_IT
dc.subjectSmall moleculesit_IT
dc.titleUrokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancerit_IT
dc.typeArticleit_IT
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record